Trevi Therapeutics reports Q4 2022 net loss $5.5M; cash $120.5M into 2026

Trevi Therapeutics, Inc.

Net loss Q4 2022: $5.5M ($0.05 per share) vs $8.5M loss same period 2021. Full-year loss $29.2M vs $33.9M.
Cash, equivalents, and marketable securities $120.5M; expects cash runway into 2026.
Plans Phase 2b dose-ranging trial of Haduvio for IPF chronic cough in H2 2023; Phase 1b respiratory study also H2 2023.
Phase 2a trial in refractory chronic cough expected to start Q3 2023.
Open-label extension data from Phase 2b/3 PRISM trial in prurigo nodularis expected Q2 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Trevi Therapeutics, Inc. reported quarter and year ended December 31, 2022 results: net income net loss of $5.5 million.

Period: quarter and year ended December 31, 2022
Net income: net loss of $5.5 million
Result: reported results

Exact text from the filing

announced its financial results for the quarter and year ended December 31, 2022

View on SEC.gov

Browse all earnings releases →

Trevi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-008459

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.